Tyra Biosciences (TYRA)
(Delayed Data from NSDQ)
$20.09 USD
-0.26 (-1.28%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $20.10 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TYRA 20.09 -0.26(-1.28%)
Will TYRA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TYRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TYRA
Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
TYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
Other News for TYRA
Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
Analysts Conflicted on These Healthcare Names: Tyra Bioscience (TYRA), Spruce Biosciences (SPRB) and UnitedHealth (UNH)
Tyra Biosciences to Present at Upcoming Investor Conferences
Buy Rating Affirmed: TYRA-300’s Progress and Potent FGFR3 Inhibition Signal Promising Outcomes for Tyra Bioscience